Home
overview

SMi’s 12th Annual Conference
RNA Therapeutics
Main Conference February 10-11, 2021 | Focus Day February 12, 2021 | London, Copthorne Tara, United Kingdom
-------------------------------------------------------------------------
RNA therapeutics is a rapidly expanding industry with increasingly growing potential for immunotherapy personalised medicines, and treatment of genetic, infectious and chronic diseases. This is reflected with the value of the global antisense & RNA therapeutics market expected to reach USD 1.81 billion by 2025, growing at a CAGR of 7.5%. Furthermore, the recent advent of CRISPR, an RNA-guided gene-editing technology, as well as new strides in the delivery of messenger RNA transcribed in vitro, have triggered a major expansion of the RNA-therapeutics field.

The 2021 conference is set to explore the latest developments in RNA delivery agents and RNA-based therapeutics with the latest case studies on advanced mRNA technologies, oligonucleotide delivery, therapeutic applications and future trends and innovations.

Join us in February 2021, as SMi’s 12th annual RNA Therapeutics Conference brings together industry experts from leading RNA therapeutics companies to gain an expert and holistic view on the latest developments in the industry, upcoming regulatory updates and industry implications.
 

  • Explore in industry insights into how mRNA is being used to combat COVID-19
  • Engage in case studies exploring the growing therapeutic potential of RNA for rare diseases
  • Delve into future trends in AI application for optimal RNA therapeutics
  • Hear regulatory outlooks of the RNA landscape, clinical trials and looking ahead

 

Key Job Titles include:

  • Research & Development Directors/Managers/Scientists
  • Heads of Clinical Development
  • Heads of Pre-Clinical Development
  • Head of RNA Biology
  • Head of RNA Formulation and Drug Delivery
  • Head of Pre-clinical R&D
  • Head of New Modalities
  • Head of Discovery
  • Senior Scientists
  • Chief Scientific Officers
  • Chief Medical Officers


Global Presence:

Attendees from all over the world attend our events, gain hands on insight from representatives from UK, Europe and USA.
 

Advanced Cell Diagnostics, A Bio-Techne Brand; Aldevron; Aldevron Llc; AMBR Consulting Ltd; AmpTec GmbH; Asahi Kasei Corporation; Astrazeneca; Bachem; BianoGMP; BioNTech RNA Pharmaceuticals; Bio-Techne Ltd; Chiesi Farmaceutici spa; eTheRNA; Ethris GmbH; F.Hoffmann-La Roche AG; Galapagos; GE Healthcare; Genevant Sciences; Genmab A/S; GSK; himed; Imperial College London; Inabata France S.A.S.; Independent; InteRNA Technologies BV; Intertek; Intertek Pharmaceutical Services Manchester; JSC R-PHARM; MHRA; Miescher Pharma GmbH; MiNA Therapeutics; MiNa Therapeutics Ltd; moderna Therapeutics; Nanogenics Ltd; New England Biolabs; NHS Blood and Transplant; NHS Blood and Transplant Authority; Nippon Fine Chemical; Nitto Avecia; Nitto Denko Avecia; Norinnova Technology Transfer AS; Pantherna Therapeutics GmbH; Polyplus-Transfection; Roche Diagnostics Deutschland; Roche Diagnostics Deutschland GmbH; Roche Innovation Center; Royal College of Surgeons in Ireland; Sanofi; Sense Biopharma AS; Symbiosis Pharmaceutical Services Limited; Thermo Fisher Scientific; TranSINE Therapeutics; Univeristy of Gent – Gene Therapy; University Gent; Vaccitech Ltd;

FEATURED SPEAKERS

Arpan Desai

Arpan Desai

Team Leader, Astrazeneca
Dong Yu

Dong Yu

Fellow, Senior Director, and Head, GSK Vaccines
Heinrich Haas

Heinrich Haas

VP RNA Formulation and Drug Developement , BioNTech RNA Pharmaceuticals
Jennifer Pluim

Jennifer Pluim

Vice President Medical Afffairs, ProQR
Maria Luisa Pineda

Maria Luisa Pineda

CEO and Co-founder, Envisagenics
Michael Mulqueen

Michael Mulqueen

VP Business Development, eTheRNA Immunotherapies
Ruchi Shah

Ruchi Shah

Senior Research Engineer, Eli Lilly and Company
Thomas Thum

Thomas Thum

Director, Institute of Molecular and Translational Therapeutic Strategies , Hannover Medical School
Troels Koch

Troels Koch

CEO & Founder, Aqiventa

Andre Müller-York

Senior Medical Affairs Director , Sarepta Therapeutics Germany GmbH
Andre  Müller-York

Arpan Desai

Team Leader, Astrazeneca
Arpan Desai

Arpan completed his first degree in Biotechnology at the University of Edinburgh, following which he obtained a PhD from the AZ/University of Nottingham Doctoral Training Centre in Targeted Therapeutics, where he studied the uptake and intracellular trafficking pathways of polymeric nanoparticles using pH-based nanosensors. He joined AZ in 2013 where he has worked primarily in the field of nucleic acid delivery. He has played a leading role in AZs formulation and delivery development activities for therapeutic nucleic acids with a focus on understanding cellular delivery mechanisms of mRNA using non-viral delivery vehicles. He has played a leading role in a number AZs collaborations to develop nucleic acid-based therapeutics including Moderna Therapeutics (mRNA), Ionis (ASOs) and Regulus (anti-miRs). More recently, he has established AZs Nucleic Acid Drug Delivery (NDD) team. This is a global discovery research focused group with the ultimate mission of apply delivery science to help advance nucleic acid based therapies into the clinic.

Cristina Reschke

Lecturer, Royal College of Surgeons in Ireland
Cristina Reschke

David Evans

Chief Scientific Officer, Sirnaomics, Inc
David Evans

Dong Yu

Fellow, Senior Director, and Head, GSK Vaccines
Dong Yu

Dr. Dong Yu is a Fellow, Senior Director, and Head of Preclinical R&D US at GSK Vaccines. He leads an organization of >80 scientists driving preclinical R&D of GSK Vaccines portfolio in the US. Dong received his PhD degree from University of Connecticut Health Center and postdoctoral training at Princeton University. He was an assistant professor at Washington University before joining GSK Vaccines (Legacy Novartis Vaccines then) in 2013. Dong has authored >40 peer-reviewed publications and is a recipient of prestigious awards such as the Investigator Award from Burroughs Wellcome and the Howard Temin Award from NIH.

Dong-Ki Lee

CEO, OilX Pharmaceuticals
Dong-Ki Lee

Heinrich Haas

VP RNA Formulation and Drug Developement , BioNTech RNA Pharmaceuticals
Heinrich Haas

Heinrich has more than 20 years of experience in academic research and industrial pharmaceutical development. His focus is on development for advanced drug delivery systems. After he received his Ph.D. in physical chemistry, he researched lipid membranes and organized biomolecular systems. He was responsible for projects in different biopharmaceutical companies for research and development of diagnostic and therapeutic carrier systems. Joining BioNTech in 2010, he helped build the formulation development and analytics unit, which develops formulations for delivery of RNA and small molecules.

Jennifer Pluim

Vice President Medical Afffairs, ProQR
Jennifer Pluim

Jennifer is Vice President, Medical Affairs at ProQR, a biotechnology company dedicated to changing lives by developing RNA therapies for rare genetic diseases, with a focused drug development on a group of blinding disorders affecting the retina, called inherited retinal diseases. Jennifer has over 25 years’ experience in the pharmaceutical industry, with extensive knowledge in clinical operations, project management and medical affairs. Her experience spans several therapeutic areas, including infectious diseases, respiratory critical care, cardiovascular disease, oncology and ophthalmology. Jennifer earned a B.S. in Microbiology with certification as a Medical Technologist and an MBA from The Pennsylvania State University USA.

Kirsty Wydenbach

Senior Medical Assessor / Deputy Unit Manager , MHRA
Kirsty Wydenbach

Dr Kirsty Wydenbach is a Senior Medical Assessor and the Deputy Unit Manager in the Clinical Trials Unit, having joined the MHRA in 2009. She has been involved in the UK regulation of clinical trials across all therapy areas and all phases of development, including ATMPs and many first-in-man studies. She has also been involved in European discussions aiming to establish an EU harmonised approach to clinical trials, particularly for Developmental Safety Update Reports (DSURs) and Reference Safety Information (RSI). She was also an EMA expert for the update of the First-in-Human guideline. Other recent work has included collaboration with external industry groups and regulators regarding adaptive and novel trial designs: she is leading on this aspect for the MHRA in order to implement that aspect of the Life Sciences Industrial Strategy, and was a contributor to the EU CTFG “Recommendation Paper on the Initiation and Conduct of Complex Clinical Trials”. More recently Kirsty has overseen the clinical trial work for COVID-19 and provided regulatory expertise on vaccines both within MHRA but also as part of the government Vaccine Taskforce.

Maria Luisa Pineda

CEO and Co-founder, Envisagenics
Maria Luisa Pineda

Dr. Maria Luisa Pineda is the co-founder and CEO of Envisagenics, Inc. a biotech spinout of Cold Spring Harbor Laboratory that integrates proprietary machine learning algorithms, high performance computing, and RNA-splicing analytics to identify disease-specific splicing variants as therapeutic targets. Envisagenics has leveraged its SpliceCore® software platform for therapeutic development with its first pipeline of assets in triple negative breast cancer. In April, Envisagenics has announced an oncology partnership leveraging SpliceCore with The Lung Cancer Initiative at Johnson & Johnson.

Michael Mulqueen

VP Business Development, eTheRNA Immunotherapies
Michael Mulqueen

Michael started his career with Roche as part of the business development department with a strong focus on in-licensing and alliance management. He left Roche to set up Synosia Therapeutics AG. From this point on, he worked with a number of European biotech companies with a focus on out-licensing and partnering. Latterly, he was VP for BD and Licensing with Silence Therapeutics in the RNAi field.

Ruchi Shah

Senior Research Engineer, Eli Lilly and Company
Ruchi Shah

Dr. Ruchi Shah received her M.S. and Ph.D in Pharmaceutical Sciences from Northeastern University in Boston, MA, USA. Her graduate work focused on development of lipid-based adjuvants for subunit vaccines in collaboration with the vaccines business of GlaxoSmithKline. Dr. Shah has led formulation and development activities of lipid-based delivery systems for mRNA and CRISPR Cas9 for both vaccines and therapeutics at GlaxoSmithKline Vaccines, Intellia Therapeutics and Moderna Therapeutics. Currently in her role at Eli Lilly and Company, she is a Senior Research Engineer in the New Therapeutics Modalities group to accelerate and develop novel therapies for unmet medical needs.

Shalini Andersson

Chief Scientist New Therapeutic Modalitiesand Head of Oligonucleotide Discovery, AstraZeneca
Shalini Andersson

Thomas Thum

Director, Institute of Molecular and Translational Therapeutic Strategies , Hannover Medical School
Thomas Thum

Thomas Thum studied medicine in Hannover, with state examination in 2001 and board examination for internal medicine/cardiology in 2009/2010. He received his PhD at the Imperial College, London (2008). He is a full professor and director of the Institute of Molecular and Translational Therapeutic Strategies at the Hannover Medical School (MHH), Visiting Professor at the Imperial College, and director of MHH’s Center for Translational Regenerative Medicine. He (co-) authors > 350 publications and is a distinguished reviewer, board member, patent holder, and founder.

Troels Koch

CEO & Founder, Aqiventa
Troels Koch

Troels Koch (TK) has 20 years’ experience in the international life science and biopharmaceutical industry. Founder of several biotech companies of which Exiqon A/S and Santaris Pharma A/S are the most commonly known. Santaris Pharma A/S was successfully exited in August 2014 – acquired by Roche, and Exiqon A/S was acquired in 2016 by Qiagen. TK has been positioned in company management teams and taken part in all aspects of executive decision making: Company strategy, VC fundraising, deal makings, partnering, IP strategy & prosecution, drug discovery and R&D. TK pioneered LNA therapeutics and has been responsible for keeping LNA antisense science and technology at an international lead position. He has worked with RNA therapeutics for 20 years and taken an active role in all steps of oligonucleotide drug discovery and development. TK has built R&D organizations up to 75 co-workers, held 100+ invited presentations at international conferences and is author of 80+ peer reviewed publications.

Exhibitors

Supporting Media Partners

Focus Days

RNA Therapeutics Focus Day
Focus Day

RNA Therapeutics Focus Day

Copthorne Tara Hotel
12th February 2021
London, United Kingdom

VENUE

Copthorne Tara Hotel

Scarsdale Place, Kensington, London, United Kingdom

The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

 

A number of our clients have been approached by third party organisations offering to book hotel rooms. We would advise that you do not book through them as they are not representing the SMi Group. SMi Group books all hotel rooms directly. If you are approached by a third party organisation then please contact us before making any bookings. If you have already booked a hotel room using a third party organisation, we would highly recommend contacting the hotel you were booked into to ensure a booking has been made for you. We would also advise you to please check the terms and conditions of the booking carefully.
HOTEL BOOKING FORM

PAST PRESENTATION - David Blakey - Mina Therapeutics

Download

PAST PRESENTATION - Surender Vashist - AstraZeneca

Download

PAST PRESENTATION - Klaus Giese - Pantherna Therapeutics

Download

PAST PRESENTATION - Heinrich Haas - BioNTech

Download

PAST PRESENTATION - Dr. Michel Janicot - InteRNA Technologies

Download

PAST PRESENTATION - David. C. Henshall - Royal College of Surgeons of Ireland

Download

PAST PRESENTATION - Dr Kirsty Wydenbach - MHRA

Download

PAST PRESENTATION - Dr Simon Newman - NanoGenics

Download

PAST PRESENTATION - David Deutsch - MHRA

Download

PAST PRESENTATION - Christopher Bunker - Advanced Cell Diagnostics

Download

PAST PRESENTATION - Bo Rode Hansen, PhD - Genevant Sciences, Inc

Download

Exhibitors


Thermo Fisher Scientific

Exhibitors
http://www.thermofisher.com/

For more than 40 years, Thermo Fisher Scientific has been a leading supplier of nucleic acid based raw materials, products and service for our customers in diagnostics, therapeutics, pharmaceutical and life science companies. With custom solutions to meet our customers unique quality and regulatory requirements, we help them succeed from development to commercialization. Visit our booth and learn about Thermo Scientific custom and OEM capabilities.

Media Partners


ASD MEDIA

Supporting Media Partners
http://www.asd-network.com

Professionals in the Aerospace & Defence market use the ASD Media internet platforms to:
  • Be informed on the latest market developments; www.asd-network.com
  • Find the latest business news; www.asd-network.com
  • Find the upcoming events; www.asd-network.com
  • Find companies and organizations; www.asdsource.com
  • Distribute news globally. www.asdwire.com
The ASD Media platforms are well known and used intensively, your company is able to benefit from these large numbers of users. Be informed with ASD-Network; Create exposure for your company with ASDSource, distribute your news with ASDWire or advertise with us, build your brand and increase traffic to your company’s website.

For more detailed information please contact with: ASD MEDIA
Stefan.koopman@asdmedia.nl


Pharmavision

Supporting Media Partners
http://www.pharmavision.co.uk

PharmaVision offers a consultancy service providing independent pharmaceutical thematic research to the healthcare industry, the investment community and competitive intelligence specialists. We perform due diligence research and provide expert commentary in healthcare. Our reports combine scientific analysis in drug delivery, R&D technologies and pharmaceutical products including patient modelling, product/technology forecasts and market trends evaluation.


Pharmalicensing

Supporting Media Partners
http://www.pharmalicensing.com

Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique online Showcase Profiling & Discover services, as well as its renowned Partnering Search service leveraging its global network of industry experts, to enable companies to identify and engage with appropriate partners around the world. Pharmalicensing is actively utilized by many tens of thousands of industry professionals each month. Pharmalicensing is a division of Cognis Group, Inc.


Farmavita

Supporting Media Partners
https://farmavitar.com

FarmavitaR+ is the professional network of experts and service providers. Network is gathering local consultants from 90 countries in Europe, Asia, North America, Latin America, Australia and Africa. Management of international, multi-centre projects is our core competence. FarmavitaR+ is providing solutions related to pharmaceutical, medical device, food supplement and cosmetic products. Scope of services is related to solutions for product development, quality assurance, clinical trials, product registration, portfolio analysis, lifecycle management, vigilance/risk management, pricing/reimbursing, market access and promotional compliance. FarmavitaR+ is brand name of Farmavita Regulanet Ltd. Visit https://farmavitar.com for more information. Outsource anything you can think of!


Technology Networks

Supporting Media Partners
http://go.technologynetworks.com/subscribe-to-newsletters

Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


Drug Discovery Today

Supporting Media Partners
http://www.drugdiscoverytoday.com/

Drug Discovery Today covers the whole of the preclinical drug discovery process. The reviews are cutting edge, written by experts in their respective fields and cover all aspects of drug discovery from genomic and proteomic approaches, computational drug design, medicinal chemistry and the translation of these sciences to therapies.


pharmaphorum

Supporting Media Partners
http://www.pharmaphorum.com

pharmaphorum drives innovation within the pharmaceutical industry, by bringing healthcare together through a suite of media services that help produce and disseminate thought leadership, combined with an online platform for communicating messages to a global audience.Visit www.pharmaphorum.com


Mednous

Supporting Media Partners
http://www.MedNous.com

MedNous is a print publication and website about medical innovation in Europe. It carries exclusive interviews with companies that are at the forefront of medical technology, as well as contributor articles from prominent practitioners. Our mission is to identify significant advances in medicine and to explain how this innovation is being commercialised. In doing so, we talk to venture capitalists about what products and platforms they are supporting. We report on how regulators cope with the accelerating pace of innovation. And we regularly cover the latest developments in the discovery and development of new medical concepts in the area of antibodies, vaccines, small molecules, regenerative medicine and nanomedicines. MedNous combines the English word for medicine with the Greek word for intellect. And those with nous are readers of our publication. Visit our website: www.mednous.com


Gene Therapy Net

Supporting Media Partners
http://www.genetherapynet.com

Gene Therapy Net is the information resource for basic and clinical research in gene therapy, and the site serves as a network in the exchange of gene therapy information and breaking news items. Visitors can keep track of the latest scientific papers, conference announcements, gene therapy jobs, regulations and guidelines


pharmanews hq

Supporting Media Partners
http://http://pharmanewshq.com

MedChemNet provides a unique and unparalleled platform for the medicinal chemistry community to share insights, discuss the latest research, and help move the field forward. MedChemNet covers all aspects of the drug discovery pipeline, from target identification and validation, through computer aided drug design (CADD), synthesis, screening and other biophysical techniques, to development of novel lead compounds and pre-clinical in vivo proof of concept. We also cover the design of synthetic drug delivery carriers and ADME/toxicology studies, as well as intellectual property and economic related issues. Website: Welcome to Pharma News HQ, the journal dedicated to the pharmaceutical and biopharmaceutical contract services. With regular sections on contract manufacturing, contract research, contract packaging, formulation/development services, contract analytical testing, APIs, stability testing, clinical research and other areas, we bring the most complete coverage of trends and issues in the industry. Pharmanewshq.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production.


Pharma Journalist

Supporting Media Partners
http://www.pharmajournalist.com

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry. Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry. Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.


Pharmacircle

Supporting Media Partners
http://www.pharmacircle.com

PharmaCircle is an innovative knowledge management company serving the current and future global leaders in the Pharmaceutical and Biotechnology related industries. PharmaCircle is a one stop information and analysis source for pipeline, products, clinical trials, drug delivery technologies, deals and acquisitions, company financials, venture capital investments, product sales, pharmaceutical services, news, patents and more….

SAVE TO


Outlook Calendar  OUTLOOK CALENDAR
Google Calendar  GOOGLE CALENDAR
ICal Calendar  ICAL CALENDAR
Yahoo! Calendar  YAHOO! CALENDAR

Copthorne Tara Hotel

Scarsdale Place
Kensington
London W8 5SR
United Kingdom

Copthorne Tara Hotel

The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

 

HOTEL BOOKING FORM

Title

SubTitle
speaker image

Content


Title


Description

Download


WHAT IS CPD?

CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

CPD AND PROFESSIONAL INSTITUTES

There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

GLOBAL CPD

Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

CPD Certificates

We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

Event Title

Headline

Text
Read More

I would like to speak at an event

I would like to attend an event

I would like to sponsor/exhibit at an event

SIGN UP OR LOGIN

Sign up
Forgotten Password?

Contact SMi GROUP LTD

UK Office
Opening Hours: 9.00 - 17.30 (local time)
SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
Registered in England No: 3779287 VAT No: GB 976 2951 71




Forgotten Password

Please enter the email address you registered with. We will email you a new password.

Thank you for visiting our event

If you would like to receive further information about our events, please fill out the information below.

By ticking above you are consenting to receive information by email from SMi.
Full details of our privacy policy can be found here https://www.smi-online.co.uk/privacy-legals/privacy-policy/.
Should you wish to update your contact preferences at any time you can contact us at data@smi-online.co.uk.
Should you wish to be removed from any future mailing lists please click on the following link http://www.smi-online.co.uk/opt-out